Cough and angioedema from angiotensin-converting enzyme inhibitors: genetic markers
Abstract
About the Authors
I. S. DantsevRussian Federation
I. I. Sinitsina
Russian Federation
D. A. Sychev
Russian Federation
References
1. Brown N.J., Vaughan D.E. Angiotensin-Converting Enzyme Inhibitors. // Circulation. 1998;97:1411-14-20.
2. Орлов В.А., Гиляревский С.Р., Урусбиева Д.М., Даурбекова Л.В. Влияние побочных эффектов иАПФ на тактику лечения сердечно-сосудистых заболеваний. // Рос. Кардиологический жур.-2005-№3.
3. Israili Z.H., Hall W.D. Cough and angioneurotic edema associated with angiotensinconverting enzyme inhibitor therapy. A review of the literature and pathophysiology. // Ann Intern Med Aug 1 1992;117(3):234—42.
4. Eck S.L., Morse J.H., Janssen D.A., Emerson S.G., Markovitz D.M. Angioedema presenting as chronic gastrointestinal symptoms. // Am J Gastroenterol Mar 1993;88(3):436—9.
5. Shahzad G., Korsten M.A., Blatt C., Motwani P. Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report. // Mt Sinai J Med Dec 2006;73(8):1123—5.
6. CKB. Tissue specific autoantibodies induced by captopril. // Clin Res 1987;35:922A.
7. Bork K., Dewald G. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. // Am J Med May 1 2004;116(9):644.
8. Chase M.P., Fiarman G.S., Scholz F.J., MacDermott R.P. Angioedema of the small bowel due to an angiotensin-converting enzyme inhibitor. // J Clin Gastroenterol Oct 2000;31(3):254—7.
9. Molinaro G., Cugno M., Perez M., et al. Angiotensin-converting enzyme inhibitorassociated angioedema is characterized by a slower degradation of des-arginine (9)-bradykinin. // J Pharmacol Exp Ther Oct 2002;303(1):232—7.
10. Pellacani A., Brunner H.R., Nussberger J. Plasma kinins increase after angiotensinconverting enzyme inhibition in human subjects. // Clin Sci (Lond) Nov 1994;87(5):567—74.
11. Lu B., Figini M., Emanueli C., Geppetti P., Grady E.F., Gerard N.P., et al. The control of microvascular permeability and blood pressure by neutral endopeptidase. // Nat Med. 1997; 3:904—907. [PubMed:9256283].
12. Kopp U.C., Farley D.M., Smith L.A. Bradykinin-mediated activation of renal sensory neurons due to prostaglandin-dependent release of substance P. // Am J Physiol. 1997; 272:R2009—R2016.[PubMed: 9227622].
13. Blais C.J., Rouleau J.L., Brown N.J., Lepage Y., Spence D., Munoz C., et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. // Immunopharmacology. 1999; 43:293—302. [PubMed: 10596866].
14. Duan Q.L., Nikpoor B., Dube M.P., Molinaro G., Meijer I.A., Dion P., et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. // Am J Hum Genet. 2005; 77:617—626. [PubMed: 16175507].
15. Bouchard L., Faucher G., Tchernof A., Deshaies Y., Lebel S., Hould F.S., et al. Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals. // Acta Diabetol. 2009; 46:13—21. [PubMed:18682883].
16. Cui J., Melista E., Chazaro I., Zhang Y., Zhou X., Manolis A.J., et al. Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. // J Hypertens. 2005; 23:55—62. [PubMed:15643125].
17. Seneviratne C., Ait-Daoud N., Ma J.Z., Chen G., Johnson B.A., Li M.D. Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. // Neuropsychopharmacology. 2009; 34:2442—2449. [PubMed: 19553914].
18. Weidinger S., Gieger C., Rodriguez E., Baurecht H., Mempel M., Klopp N., et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. // PLoS Genet. 2008; 4:e1000166. [PubMed: 18846228].
19. Sleiman P.M., Flory J., Imielinski M., Bradfield J.P., Annaiah K., Willis-Owen S.A., et al. Variants of DENND1B associated with asthma in children. // N Engl J Med. 2010; 362:36—44. [PubMed:20032318].
20. Суворов Н.В., Чельцов В.В., Илларионова Т.С, Астахова А.В., Коровякова Э.А. Ингибиторы ангиотензинпревращающего фермента: неблагоприятные побочные реакции. // Вестник РУДН, серия Медицина 2004 №3(27).
21. Rigat B., Hubert C., Corvol P., Soubrier F. PCR detection of the incertion/deletion polymorphism of the human ACE gene (DCP1) (dipeptidyl carboxypeptidase 1). // Nucl. Acids Res. 1990. V.20. P.1433.
22. Banerji A.S., Clark M. Blanda, F. LoVecchio, B. Snyder, and C. A. Camargo Jr. 2008. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. // Ann. Allergy Asthma Immunol. 100:327—332.
23. Samuel Michael Lipski, Georges Casimir, Martine Vanlommel1, Mathieu Jeanmaire & Pierre Dolhen. Angiotensin-converting enzyme inhibitorsinduced angioedema treated by C1 esterase inhibitor concentrate (Berinert): about one case and review of the therapeutic arsenal. // Clinical Case Reports 2015; 3(2): 126—130.
24. Korniyenko A., Alviar C.L., Cordova J.P., Messerli F.H. Visceral angioedema due to angiotensin-converting enzyme inhibitor therapy. // Cleve Clin J Med 2011; 78(5): 297_304.
25. Toh S., et al. Comparative risk for angioedema associated with the use of drugs that target the rennin-angiotensin-aldosterone system. // Arch. Intern. Med. 2012;172:1582-1589.
26. Brown N.J., Snowden M., Griffin M.R. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. // JAMA. 1997;278:232-233.
27. Beltrami L., Zanichelli A., Zingale L., Vacchini R., Carugo S., Cicardi M. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. // J. Hypertens. 2011;29:2273-2277.
28. Fitzharris P., Jordan A. Investigating recurrent angioedema. // BMJ. 2011;343:d6607.
29. Coelho M.L., Amaral R., Curvo-Semedo L., Caseiro-Alves F. Small bowel angioedema induced by angiotensin converting enzyme (ACE) inhibitor: US and CT fi ndings. // JBR-BTR. 2014 Jul-Aug;97(4):239-41.
30. Cohen N., Sharon A., Golik A., Zaidenstein R., Modai D. Hereditary angioneurotic edema with severe hypovolemic shock. // J Clin Gastroenterol Apr 1993;16(3):237—9.
31. Ежова Г.П., Бабаев А.А., Новиков В.В. Биоинформационные аспекты протеомики и деградации белка. // Учебно-методические материалы/ Нижний Новгород 2007.
32. Kostis J.B., Packer M., Black H.R., Schmieder R., Henry D., Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. // Am J Hypertens. 2004; 17:103—111. [PubMed: 14751650].
33. Prashanth M. Thalanayar, Ibrahim Ghobrial, Fritz Lubin, Reena Karnik, and Robin Bhasin. Drug-induced visceral angioedema. // Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25260.
34. Woodard-Grice A.V., Lucisano A.C., Byrd J.B., Stone E.R., Simmons W.H., Brown N.J. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. // Pharmacogenet Genomics. 2010; 20:532-536.
35. Guillaume Parea, Michiaki Kuboj, James B. Byrde, Catherine A. McCartyf, Alencia Woodard-Griceg, Koon K. Teob, Sonia S. Anandc,d, Rebecca L. Zuvichh, Yuki Bradfordh, Stephanie Rossa, Yusuke Nakamurak, Marylyn Ritchiei, and Nancy J. Browng. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. // Pharmacogenet Genomics. 2013 September; 23(9): 470—478. doi: 10.1097/FPC.0b013e328363c137.
36. Delgoffe G.M., Pollizzi K.N., Waickman A.T., Heikamp E., Meyers D.J., Horton M.R., et al. The kinasemTOR regulates the differentiation of helper T cells through the selective activation of signalingby mTORC1 and mTORC2. // Nat Immunol. 2011; 12:295—303.
Review
For citations:
Dantsev I.S., Sinitsina I.I., Sychev D.A. Cough and angioedema from angiotensin-converting enzyme inhibitors: genetic markers. Pharmacogenetics and Pharmacogenomics. 2015;(2):9-13. (In Russ.)